External assessment of the Early Mortality Risk Score in patients with adenocarcinoma undergoing pancreaticoduodenectomy.
Détails
Télécharger: 1-s2.0-S1365182X15312375-main.pdf (185.55 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_D46FD77C206F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
External assessment of the Early Mortality Risk Score in patients with adenocarcinoma undergoing pancreaticoduodenectomy.
Périodique
Hpb : the Official Journal of the International Hepato Pancreato Biliary Association
ISSN
1477-2574 (Electronic)
ISSN-L
1365-182X
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
17
Numéro
7
Pages
605-610
Langue
anglais
Notes
Publication types: Evaluation Studies ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
BACKGROUND: Pancreaticoduodenectomies (PD) still have a substantial mortality rate. Recently, different scores have been published to predict the mortality risk pre-operatively after PD. This retrospective study was designed to perform an external assessment of an Early Mortality Risk Score (EMRS).
METHODS: From 2000 to 2012, all PD cases performed at our institution were documented. Only patients treated for pancreatic head adenocarcinomas were included. Survival time and EMRS (based on age, tumour size, tumour differentiation and comorbidities) were calculated for every patient. Relative risks (RR) of early death 9 and 12 months after PD were then calculated.
RESULTS: Of 270 PD for various aetiologies, 120 PD for adenocarcinomas were included. The median follow-up was 37 months, and the overall median survival was 19 months. EMRS of 4 showed a mortality RR of 5.1 at 9 months (P = 0.048) and of 4.5 at 12 months (P = 0.020).
CONCLUSIONS: EMRS of 4 is a predictor of tumour-related mortality at 9 and 12 months after PD for adenocarcinoma. The EMRS was externally assessed in our patient cohort and can be implemented in clinical practice. Clinical implications of this score still need to be studied.
METHODS: From 2000 to 2012, all PD cases performed at our institution were documented. Only patients treated for pancreatic head adenocarcinomas were included. Survival time and EMRS (based on age, tumour size, tumour differentiation and comorbidities) were calculated for every patient. Relative risks (RR) of early death 9 and 12 months after PD were then calculated.
RESULTS: Of 270 PD for various aetiologies, 120 PD for adenocarcinomas were included. The median follow-up was 37 months, and the overall median survival was 19 months. EMRS of 4 showed a mortality RR of 5.1 at 9 months (P = 0.048) and of 4.5 at 12 months (P = 0.020).
CONCLUSIONS: EMRS of 4 is a predictor of tumour-related mortality at 9 and 12 months after PD for adenocarcinoma. The EMRS was externally assessed in our patient cohort and can be implemented in clinical practice. Clinical implications of this score still need to be studied.
Mots-clé
Adenocarcinoma/mortality, Adenocarcinoma/pathology, Age Factors, Aged, Cell Differentiation, Comorbidity, Decision Support Techniques, Female, Humans, Kaplan-Meier Estimate, Male, Pancreatic Neoplasms/mortality, Pancreatic Neoplasms/pathology, Pancreaticoduodenectomy/adverse effects, Pancreaticoduodenectomy/mortality, Predictive Value of Tests, Retrospective Studies, Risk Assessment, Risk Factors, Switzerland, Time Factors, Treatment Outcome, Tumor Burden
Pubmed
Web of science
Open Access
Oui
Création de la notice
06/07/2015 12:40
Dernière modification de la notice
28/04/2023 6:15